La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Lipella Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Lipella Pharmaceuticals..

Lipella Pharmaceuticals (NASDAQ:LIPO) Azioni, Catena delle Opzioni

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

<p><strong>BlackBerry Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) shares are trading<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> relatively flat in the morning session on Thursday.</a></p>
<p>Yesterday, the company announced that Hyundai Mobis, a subsidiary of the <strong>Hyundai Motor Grou</strong>p (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>), has selected BlackBerry QNX<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac41793335/hyundai-mobis-selects-blackberry-qnx-to-power-next-generation-digital-cockpit-platform" rel="noreferrer noopener"> to power its next-generation digital cockpit platform.</a></p>
<p>Hyundai Mobis will use BlackBerry&#8217;s QNX Hypervisor for Safety&nbsp;and&nbsp;QNX Advanced Virtualization Frameworks&nbsp;(QAVF) for its next-generation digital cockpit platform.</p>
<p>&#8220;With BlackBerry QNX technology underpinning our next generation digital cockpit platform, together we are helping to deliver a smarter and more technologically sophisticated future for drivers and passengers alike, without sacrificing safety, security or reliability,&#8221; said Sung-Hoon Lee, SVP of Sales Division at Hyundai Mobis.</p>
<p>QNX&#8217;s foundational software supports digital cockpits and advanced driver assistance systems (ADAS) to infotainment systems and domain controllers at lower cost.</p>
<p><strong>Also Read:<a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/41794596/bitcoin-ethereum-dogecoin-slingshot-to-the-moon-after-trump-victory-but-sharp-correction-m" rel="noreferrer noopener"> Bitcoin, Ethereum, Dogecoin Slingshot To The Moon After Trump Victory But &#8216;Sharp&#8217; Correction Might Be In Store: Analyst Views BTC Between $80-90K By End Of Year</a></strong></p>
<p>&#8220;We&#8217;re confident that automakers worldwide will embrace Hyundai Mobis&#8217; cutting-edge digital cockpit platform as they enhance the safety and personalization of the in-car experience,&#8221; said Dhiraj Handa, VP, Asia Pacific region at BlackBerry QNX.</p>
<p>On October 31, BlackBerry announced an expansion of its long-standing collaboration by inking a pact of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/ac41650377/blackberry-qnx-introduces-software-defined-functional-safety-platform-in-collaboration-with-intel" rel="noreferrer noopener">BlackBerry QNX with Intel Corporation</a>.&nbsp;</p>
<p>Last month, the company announced details of profitability for its IoT and Cybersecurity divisions, including&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41364627/why-blackberry-shares-are-gaining-today" rel="noreferrer noopener">strategic options for the Cylance business.</a></p>
<p>BlackBerry projected FY25 cyber revenues between $350 million and $365 million and optimistic about achieving break-even results, signaling a potential turnaround after previous challenges.</p>
<p>In a press release dated<a target="_blank" href="https://www.blackberry.com/us/en/pdfviewer?file=/content/dam/bbcomv4/blackberry-com/en/company/investors/financial-reports/2025/q22025/Q2-FY25-Earnings-Press-Release.pdf" rel="noreferrer noopener"> September 26</a>, the company said it expects FY25 revenues of $591 million – $616 million.</p>
<p>According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BB stock has lost 39% in the past year.</p>
<p><strong>Price Action: </strong>BB shares are trading higher by 0.31% to $2.297 at last check Thursday.</p>
<p><strong>Read Next:&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41778985/the-bitcoin-act-of-2024-is-a-significant-proposal-will-it-redefine-us-crypto-regulation" target="_blank" rel="noreferrer noopener">The BITCOIN Act Of 2024 ‘Is A Significant Proposal' — Will It Redefine US Crypto Regulation?</a></strong></li>
</ul>


Equities

News

Markets

General

HYMTF

BlackBerry Powers Up: Hyundai Mobis Chooses QNX For Next-Gen Digital Cockpit

<p><strong>Welltower</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) just disclosed its Q3 earnings on Monday, October 28, 2024 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Welltower beat estimated earnings by 7.000000000000001%, reporting an EPS of $1.11 versus an estimate of $1.04.</p>
<p>Revenue was up $394.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.04 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Welltower's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.04</td>
<td>1.01</td>
<td>0.94</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.11</td>
<td>1.05</td>
<td>1.01</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.95B</td>
<td>1.89B</td>
<td>1.81B</td>
<td>1.75B</td>
<td>1.63B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.06B</td>
<td>1.82B</td>
<td>1.56B</td>
<td>1.75B</td>
<td>1.66B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Welltower management provided guidance for FY 2024, expecting earnings between $4.27 and $4.33 per share.</p>
<h3>Peer Performance in Recent Earnings</h3>
<p>With Welltower's earnings data now available, it's crucial to gauge how its competitors, including Healthpeak Properties, Sabra Health Care REIT, and National Health Investors, have been performing.</p>
<ul>
<li>Healthpeak Properties, earnings revealed on October 24, 2024, exhibited robust performance this quarter. Contrary to the market's projected EPS of $0.44, Healthpeak Properties exceeded expectations with an EPS of $0.45, reflecting an increase of 2.27% compared to estimates. This outcome is likely to gain investor confidence</li>
<li>Sabra Health Care REIT announced strong earnings on October 31, 2024, surpassing market expectations. Despite an estimated EPS of $0.35, Sabra Health Care REIT's actual EPS was $0.35, reflecting a 0.0% increase.</li>
<li>The latest earnings report from National Health Investors on November 05, 2024 showed a downturn in performance, with results falling short of expectations. Despite the market's EPS estimate of $1.08, National Health Investors reported an EPS of $1.03, marking a -4.63% decrease.</li>
</ul>
<h3>Analysis of Competitors' Quarterly Earnings and Stock Performance</h3>
<p>The analysis presented here offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welltower</td>
<td>October 28, 2024</td>
<td style="text-align: right;">1.04</td>
<td style="text-align: right;">1.11</td>
<td>6.73%</td>
<td>$130.57</td>
<td>$133.62</td>
<td>2.34%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>October 24, 2024</td>
<td style="text-align: right;">0.44</td>
<td style="text-align: right;">0.45</td>
<td>2.27%</td>
<td>$23.0</td>
<td>$22.66</td>
<td>-1.48%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>October 31, 2024</td>
<td style="text-align: right;">0.35</td>
<td style="text-align: right;">0.35</td>
<td>0.0%</td>
<td>$19.4</td>
<td>$19.78</td>
<td>1.96%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>November 05, 2024</td>
<td style="text-align: right;">1.08</td>
<td style="text-align: right;">1.03</td>
<td>-4.63%</td>
<td>$76.73</td>
<td>$76.75</td>
<td>0.03%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
<p>The comparison table below presents estimated and announced revenue figures for Welltower's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welltower</td>
<td>1.95B</td>
<td>2.06B</td>
<td>5.44%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>688.98M</td>
<td>700.40M</td>
<td>1.66%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>172.34M</td>
<td>178.00M</td>
<td>3.28%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>79.21M</td>
<td>82.94M</td>
<td>4.72%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Welltower <a href="https://www.benzinga.com/quote/WELL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

WELL

Welltower Earnings Report: Q3 Overview

Trading Ideas

DXYZ

Destiny Tech100 Inc. Shares Resume Trade

<p>Piper Sandler  analyst Matt Farrell   reiterates Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Overweight and raises the price target from $13 to $18.</p>


Price Target

Reiteration

Analyst Ratings

UPWK

Piper Sandler Reiterates Overweight on Upwork, Raises Price Target to $18

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and maintains $54 price target.</p>


Telsey Advisory Group Maintains Outperform on Tapestry, Maintains $54 Price Target

<p>Benchmark  analyst Mike Hickey   reiterates AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) with a Hold.</p>


Benchmark Reiterates Hold on AMC Enter Hldgs

Destiny Tech100 Inc. Shares Halted To The Upside; Stock Now Up 42.35%

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) with a Market Perform and maintains $3 price target.</p>


OLPX

Telsey Advisory Group Maintains Market Perform on Olaplex Hldgs, Maintains $3 Price Target

<p>Piper Sandler  analyst Matt Farrell   reiterates Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) with a Neutral and raises the price target from $7 to $8.</p>


BMBL

Piper Sandler Reiterates Neutral on Bumble, Raises Price Target to $8

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $50 price target.</p>


SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $50 Price Target

<p><strong>Hyatt Hotels</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) announced its Q3 earnings on Thursday, October 31, 2024 at 06:55 AM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Hyatt Hotels missed estimated earnings by -32.0%, reporting an EPS of $0.94 versus an estimate of $1.38.</p>
<p>Revenue was up $7.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.36, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at Hyatt Hotels's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.38</td>
<td>1.17</td>
<td>0.92</td>
<td>0.39</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.94</td>
<td>1.53</td>
<td>0.71</td>
<td>0.64</td>
<td>0.70</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.57B</td>
<td>1.74B</td>
<td>1.71B</td>
<td>1.60B</td>
<td>1.64B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.63B</td>
<td>1.70B</td>
<td>1.71B</td>
<td>1.66B</td>
<td>1.62B</td>
</tr>
</tbody>
</table>
</p>
<h3>Peer Performance in Recent Earnings</h3>
<p>With Hyatt Hotels's earnings data in hand, it's essential to compare its metrics to those of similar companies, including Norwegian Cruise Line, Viking Holdings, and Global Business Travel.</p>
<ul>
<li>Norwegian Cruise Line, earnings revealed on October 31, 2024, exhibited robust performance this quarter. Contrary to the market's projected EPS of $0.94, Norwegian Cruise Line exceeded expectations with an EPS of $0.99, reflecting an increase of 5.32% compared to estimates. This outcome is likely to gain investor confidence</li>
<li>Viking Holdings reported earnings on August 22, 2024 that fell short of expectations, with an actual EPS of $0.37 compared to the market's estimate of $0.65, resulting in a -43.08% decrease.</li>
<li>On November 05, 2024, Global Business Travel unveiled earnings that were below market expectations, with an actual EPS of $-0.28 compared to an estimated EPS of $-0.03, resulting in a -833.33% decrease.</li>
</ul>
<h3>Unpacking Competitors' Quarterly Earnings and Stock Performance</h3>
<p>This analytical review offers valuable insights into how the market has perceived the most recent earnings updates from major competitors. It outlines the forecasted and disclosed earnings per share (EPS) for each company, as well as the related stock prices at the end of the announcement day and the start of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyatt Hotels</td>
<td>October 31, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">0.94</td>
<td>-31.88%</td>
<td>$145.45</td>
<td>$145.42</td>
<td>-0.02%</td>
</tr>
<tr>
<td>Norwegian Cruise Line</td>
<td>October 31, 2024</td>
<td style="text-align: right;">0.94</td>
<td style="text-align: right;">0.99</td>
<td>5.32%</td>
<td>$25.34</td>
<td>$25.25</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Viking Holdings</td>
<td>August 22, 2024</td>
<td style="text-align: right;">0.65</td>
<td style="text-align: right;">0.37</td>
<td>-43.08%</td>
<td>$33.22</td>
<td>$33.83</td>
<td>1.84%</td>
</tr>
<tr>
<td>Global Business Travel</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.28</td>
<td>-833.33%</td>
<td>$7.73</td>
<td>$7.87</td>
<td>1.81%</td>
</tr>
</tbody>
</table>
</p>
<h3>Peer Revenue Comparison: Estimated vs. Announced Revenue</h3>
<p>Here's a comparison table presenting estimated and announced revenue figures for Hyatt Hotels's peers. This comparison offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyatt Hotels</td>
<td>1.57B</td>
<td>1.63B</td>
<td>3.76%</td>
</tr>
<tr>
<td>Norwegian Cruise Line</td>
<td>2.77B</td>
<td>2.81B</td>
<td>1.34%</td>
</tr>
<tr>
<td>Viking Holdings</td>
<td>1.43B</td>
<td>1.59B</td>
<td>10.98%</td>
</tr>
<tr>
<td>Global Business Travel</td>
<td>613.53M</td>
<td>597M</td>
<td>-2.69%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Hyatt Hotels <a href="https://www.benzinga.com/quote/H/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hyatt Hotels Earnings Review: Q3 Summary

TTEC

TTEC Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Down -15.5%

Offerings

IPOs

ADUR

Aduro Clean Technologies Prices $4M Offering  Of 941,177 Shares At $4.25/Share

<p>Benchmark  analyst Mark Zgutowicz   maintains LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) with a Buy and lowers the price target from $48 to $42.</p>


RAMP

Benchmark Maintains Buy on LiveRamp Holdings, Lowers Price Target to $42

<p>Barrington Research  analyst Alexander Paris   maintains Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) with a Outperform and raises the price target from $165 to $180.</p>


LOPE

Barrington Research Maintains Outperform on Grand Canyon Education, Raises Price Target to $180

<p>Truist Securities  analyst Michael Ciarmoli   maintains VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) with a Buy and raises the price target from $115 to $133.</p>


VSEC

Truist Securities Maintains Buy on VSE, Raises Price Target to $133

<p>Barrington Research  analyst Gary Prestopino   maintains Openlane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAR#NYSE">KAR</a>) with a Outperform and maintains $25 price target.</p>


Barrington Research Maintains Outperform on Openlane, Maintains $25 Price Target

<p>Truist Securities  analyst Scot Ciccarelli   maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Buy and raises the price target from $455 to $459.</p>


Truist Securities Maintains Buy on Home Depot, Raises Price Target to $459

YORW

York Water Q3 EPS $0.41 Down From $0.53 YoY; Operating Revenue $19.715M Up From $18.767M YoY

<p>Benchmark  analyst Mark Zgutowicz   maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Buy and lowers the price target from $42 to $40.</p>


KVYO

Benchmark Maintains Buy on Klaviyo, Lowers Price Target to $40

Lipella Pharmaceuticals stock falls after it prices $1.28M direct offering

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Lipella Pharmaceuticals, Inc. (LIPO – Research Report), retaining the price target...

Buy Rating Affirmed: Lipella Pharmaceuticals' Innovative Drug Delivery and Clinical Advancements Propel Optimism

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Lipella Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lipo-stock-quote/"><strong>LIPO</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Lipella Pharmaceuticals reported earnings per share of -12 cents.</li><li>The company reported revenue of $136,431.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/lipo-stock-earnings-lipella-pharmaceuticals-for-q2-of-2024/">LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q2 2024

Lipella Pharmaceuticals, Inc. (LIPO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ja...

Buy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus Treatment

Warning: LIPO is at high risk of performing badly

Lipella Pharmaceuticals announces 1-for-8 reverse stock split

LIPO

Biotech

Health Care

Press Releases

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

Comments

Lipella Pharmaceuticals

Lipella Pharmaceuticals (LIPO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO